Search

Your search keyword '"Kagucia, Eunice W."' showing total 12 results
Start Over Author "Kagucia, Eunice W."
12 results on '"Kagucia, Eunice W."'

1. Global Impact of 10- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in All Ages: The PSERENADE Project

Author

Bennett, Julia C., primary, Knoll, Maria D., additional, Kagucia, Eunice W., additional, Garcia Quesada, Maria, additional, Zeger, Scott L, additional, Hetrich, Marissa K., additional, Yang, Yangyupei, additional, Herbert, Carly B., additional, Ogyu, Anju, additional, Cohen, Adam L., additional, Yildirim, Inci, additional, Winje, Brita A., additional, Von Gottberg, Ann, additional, Viriot, Delphine, additional, van der Linden, Mark, additional, Valentiner-Branth, Palle, additional, Suga, Shigeru, additional, Steens, Anneke, additional, Skoczyńska, Anna, additional, Sinkovec Zorko, Nadja, additional, Scott, J. Anthony G., additional, Savulescu, Camelia, additional, Savrasova, Larisa, additional, Sanz, Juan Carlos, additional, Russell, Fiona M., additional, Ricketson, Leah J., additional, Puentes, Rodrigo, additional, Nuorti, J. Pekka, additional, Mereckiene, Jolita, additional, McMahon, Kimberley, additional, McGeer, Allison, additional, Mad'arová, Lucia, additional, Mackenzie, Grant, additional, MacDonald, Laura, additional, Lepp, Tiia, additional, Ladhani, Shamez, additional, Kristinsson, Karl G., additional, Kozakova, Jana, additional, Klein, Nicola P., additional, Jayasinghe, Sanjay, additional, Ho, Pak-Leung, additional, Hilty, Markus, additional, Heyderman, Robert S., additional, Hasanuzzaman, Md., additional, Hammitt, Laura L., additional, Guevara, Marcela, additional, Grgic-Vitek, Marta, additional, Gierke, Ryan, additional, Georgakopoulou, Theano, additional, Galloway, Yvonne M., additional, Diawara, Idrissa, additional, Desmet, Stefanie, additional, De Wals, Philippe, additional, Dagan, Ron, additional, Colzani, Edoardo, additional, Cohen, Cheryl, additional, Ciruela, Pilar, additional, Chuluunbat, Urtnasan, additional, Chan, Guanhao, additional, Camilli, Romina, additional, Bruce, Michael G., additional, Brandileone, Maria-Cristina C., additional, Bigogo, Godfrey M., additional, Ampofo, Krow, additional, Feikin, Daniel R., additional, Hayford, Kyla, additional, and PSERENADE Team, The, additional

Published
2024
Full Text
View/download PDF

2. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

Author

Adetifa, Ifedayo M. O., Uyoga, Sophie, Gitonga, John N., Mugo, Daisy, Otiende, Mark, Nyagwange, James, Karanja, Henry K., Tuju, James, Wanjiku, Perpetual, Aman, Rashid, Mwangangi, Mercy, Amoth, Patrick, Kasera, Kadondi, Ng’ang’a, Wangari, Rombo, Charles, Yegon, Christine, Kithi, Khamisi, Odhiambo, Elizabeth, Rotich, Thomas, Orgut, Irene, Kihara, Sammy, Bottomley, Christian, Kagucia, Eunice W., Gallagher, Katherine E., Etyang, Anthony, Voller, Shirine, Lambe, Teresa, Wright, Daniel, Barasa, Edwine, Tsofa, Benjamin, Bejon, Philip, Ochola-Oyier, Lynette I., Agweyu, Ambrose, Scott, J. Anthony G., and Warimwe, George M.

Published
2021
Full Text
View/download PDF

3. Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

Author

Feikin, Daniel R, Kagucia, Eunice W, Loo, Jennifer D, Link-Gelles, Ruth, Puhan, Milo A, Cherian, Thomas, Levine, Orin S, Whitney, Cynthia G, O’Brien, Katherine L, and Moore, Matthew R

Subjects
Immunization, Prevention, Vaccine Related, Lung, Biotechnology, Clinical Research, Infection, Adolescent, Adult, Aged, Child, Preschool, Databases as Topic, Health Planning Guidelines, Heptavalent Pneumococcal Conjugate Vaccine, Humans, Meningitis, Pneumococcal, Meta-Analysis as Topic, Pneumococcal Infections, Pneumococcal Vaccines, Population Surveillance, Serotyping, Young Adult, Serotype Replacement Study Group, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundVaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined substantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs. Increases in non-vaccine-serotype (NVT) IPD rates occurred in some sites, presumably representing serotype replacement. We used a standardized approach to describe serotype-specific IPD changes among multiple sites after PCV7 introduction.Methods and findingsOf 32 IPD surveillance datasets received, we identified 21 eligible databases with rate data ≥ 2 years before and ≥ 1 year after PCV7 introduction. Expected annual rates of IPD absent PCV7 introduction were estimated by extrapolation using either Poisson regression modeling of pre-PCV7 rates or averaging pre-PCV7 rates. To estimate whether changes in rates had occurred following PCV7 introduction, we calculated site specific rate ratios by dividing observed by expected IPD rates for each post-PCV7 year. We calculated summary rate ratios (RRs) using random effects meta-analysis. For children

Published
2013

6. SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021

Author

Etyang, Anthony O., primary, Adetifa, Ifedayo, additional, Omore, Richard, additional, Misore, Thomas, additional, Ziraba, Abdhalah K., additional, Ng’oda, Maurine A., additional, Gitau, Evelyn, additional, Gitonga, John, additional, Mugo, Daisy, additional, Kutima, Bernadette, additional, Karanja, Henry, additional, Toroitich, Monica, additional, Nyagwange, James, additional, Tuju, James, additional, Wanjiku, Perpetual, additional, Aman, Rashid, additional, Amoth, Patrick, additional, Mwangangi, Mercy, additional, Kasera, Kadondi, additional, Ng’ang’a, Wangari, additional, Akech, Donald, additional, Sigilai, Antipa, additional, Karia, Boniface, additional, Karani, Angela, additional, Voller, Shirine, additional, Agoti, Charles N., additional, Ochola-Oyier, Lynette I., additional, Otiende, Mark, additional, Bottomley, Christian, additional, Nyaguara, Amek, additional, Uyoga, Sophie, additional, Gallagher, Katherine, additional, Kagucia, Eunice W., additional, Onyango, Dickens, additional, Tsofa, Benjamin, additional, Mwangangi, Joseph, additional, Maitha, Eric, additional, Barasa, Edwine, additional, Bejon, Philip, additional, Warimwe, George M., additional, Scott, J. Anthony G., additional, and Agweyu, Ambrose, additional

Published
2022
Full Text
View/download PDF

7. Changes in Invasive Pneumococcal Disease Caused by Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project

Author

Bennett, Julia C, Hetrich, Marissa K, Quesada, Maria Garcia, Sinkevitch, Jenna N, Knoll, Maria Deloria, Feikin, Daniel R, Zeger, Scott L, Kagucia, Eunice W, Cohen, Adam L, Ampofo, Krow, Brandileone, Maria-Cristina C, Bruden, Dana, Camilli, Romina, Castilla, Jesús, Chan, Guanhao, Cook, Heather, Cornick, Jennifer E, Dagan, Ron, Dalby, Tine, Danis, Kostas, Miguel, Sara de, Wals, Philippe De, Desmet, Stefanie, Georgakopoulou, Theano, Gilkison, Charlotte, Grgic-Vitek, Marta, Hammitt, Laura L, Hilty, Markus, Ho, Pak-Leung, Jayasinghe, Sanjay, Kellner, James D, Kleynhans, Jackie, Knol, Mirjam J, Kozakova, Jana, Kristinsson, Karl G, Ladhani, Shamez N, MacDonald, Laura, Mackenzie, Grant A, Mad'arová, Lucia, McGeer, Allison, Mereckiene, Jolita, Morfeldt, Eva, Mungun, Tuya, Muñoz-Almagro, Carmen, Nuorti, J Pekka, Paragi, Metka, Pilishvili, Tamara, Puentes, Rodrigo, Saha, Samir K, Khan, Aalisha Sahu, Savrasova, Larisa, Scott, J Anthony, Skoczyńska, Anna, Suga, Shigeru, Linden, Mark van der, Verani, Jennifer R, Gottberg, Anne von, Winje, Brita A, Yildirim, Inci, Zerouali, Khalid, Hayford, Kyla, and The Pserenade Team

Subjects
serotypes, pneumococcal conjugate vaccines, vaccine impact, invasive pneumococcal disease
Abstract

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for

Published
2021

8. Prevalence of SARS-CoV-2 Antibodies from a one-year National Serosurveillance of Kenyan Blood Transfusion Donors

Author

Uyoga, Sophie, primary, Adetifa, Ifedayo M.O., additional, Otiende, Mark, additional, Gitonga, John N., additional, Mugo, Daisy, additional, Nyagwange, James, additional, Karanja, Henry K., additional, Tuju, James, additional, Makale, Johnstone, additional, Aman, Rashid, additional, Mwangangi, Mercy, additional, Amoth, Patrick, additional, Kasera, Kadondi, additional, Ng’ang’a, Wangari, additional, Kilonzo, Nduku, additional, Chege, Evelynn, additional, Yegon, Christine, additional, Odhiambo, Elizabeth, additional, Rotich, Thomas, additional, Orgut, Irene, additional, Kihara, Sammy, additional, Bottomley, Christian, additional, Kagucia, Eunice W., additional, Gallagher, Katherine E., additional, Etyang, Anthony, additional, Voller, Shirine, additional, Lambe, Teresa, additional, Wright, Daniel, additional, Barasa, Edwine, additional, Tsofa, Benjamin, additional, Mwangangi, Joseph, additional, Bejon, Philip, additional, Ochola-Oyier, Lynette I., additional, Warimwe, George M., additional, Agweyu, Ambrose, additional, and Scott, J. Anthony G., additional

Published
2021
Full Text
View/download PDF

9. Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya

Author

Adetifa, Ifedayo M.O., primary, Uyoga, Sophie, additional, Gitonga, John N., additional, Mugo, Daisy, additional, Otiende, Mark, additional, Nyagwange, James, additional, Karanja, Henry K., additional, Tuju, James, additional, Wanjiku, Perpetual, additional, Aman, Rashid, additional, Mwangangi, Mercy, additional, Amoth, Patrick, additional, Kasera, Kadondi, additional, Ng’ang’a, Wangari, additional, Rombo, Charles, additional, Yegon, Christine, additional, Kithi, Khamisi, additional, Odhiambo, Elizabeth, additional, Rotich, Thomas, additional, Orgut, Irene, additional, Kihara, Sammy, additional, Bottomley, Christian, additional, Kagucia, Eunice W., additional, Gallagher, Katherine E., additional, Etyang, Anthony, additional, Voller, Shirine, additional, Lambe, Teresa, additional, Wright, Daniel, additional, Barasa, Edwine, additional, Tsofa, Benjamin, additional, Bejon, Philip, additional, Ochola-Oyier, Lynette I., additional, Agweyu, Ambrose, additional, Scott, J. Anthony G., additional, and Warimwe, George M., additional

Published
2021
Full Text
View/download PDF

10. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors

Author

Uyoga, Sophie, primary, Adetifa, Ifedayo M. O., additional, Karanja, Henry K., additional, Nyagwange, James, additional, Tuju, James, additional, Wanjiku, Perpetual, additional, Aman, Rashid, additional, Mwangangi, Mercy, additional, Amoth, Patrick, additional, Kasera, Kadondi, additional, Ng’ang’a, Wangari, additional, Rombo, Charles, additional, Yegon, Christine, additional, Kithi, Khamisi, additional, Odhiambo, Elizabeth, additional, Rotich, Thomas, additional, Orgut, Irene, additional, Kihara, Sammy, additional, Otiende, Mark, additional, Bottomley, Christian, additional, Mupe, Zonia N., additional, Kagucia, Eunice W., additional, Gallagher, Katherine E., additional, Etyang, Anthony, additional, Voller, Shirine, additional, Gitonga, John N., additional, Mugo, Daisy, additional, Agoti, Charles N., additional, Otieno, Edward, additional, Ndwiga, Leonard, additional, Lambe, Teresa, additional, Wright, Daniel, additional, Barasa, Edwine, additional, Tsofa, Benjamin, additional, Bejon, Philip, additional, Ochola-Oyier, Lynette I., additional, Agweyu, Ambrose, additional, Scott, J. Anthony G., additional, and Warimwe, George M., additional

Published
2021
Full Text
View/download PDF

11. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.

Author

Deloria Knoll, Maria, Bennett, Julia C., Garcia Quesada, Maria, Kagucia, Eunice W., Peterson, Meagan E., Feikin, Daniel R., Cohen, Adam L., Hetrich, Marissa K., Yang, Yangyupei, Sinkevitch, Jenna N., Ampofo, Krow, Aukes, Laurie, Bacci, Sabrina, Bigogo, Godfrey, Brandileone, Maria-Cristina C., Bruce, Michael G., Camilli, Romina, Castilla, Jesús, Chan, Guanhao, and Chanto Chacón, Grettel

Subjects
LOW-income countries, CONSUMER preferences, PNEUMOCOCCAL vaccines, ADULTS
Abstract

Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project.

Author

Bennett, Julia C., Hetrich, Marissa K., Garcia Quesada, Maria, Sinkevitch, Jenna N., Deloria Knoll, Maria, Feikin, Daniel R., Zeger, Scott L., Kagucia, Eunice W., Cohen, Adam L., Ampofo, Krow, Brandileone, Maria-Cristina C., Bruden, Dana, Camilli, Romina, Castilla, Jesús, Chan, Guanhao, Cook, Heather, Cornick, Jennifer E., Dagan, Ron, Dalby, Tine, and Danis, Kostas

Subjects
STREPTOCOCCUS pneumoniae, PNEUMOCOCCAL vaccines, POISSON regression, INFANTS
Abstract

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3 + 0 schedule constrains generalizability and data from these settings are needed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results